Myriad Genetics Collaborates with Flatiron Health for Better Cancer Care
Myriad Genetics, a pioneer in genetic testing and precision medicine, has taken a significant step towards enhancing accessibility to genetic tests with its latest collaboration with Flatiron Health, a leading health tech company specializing in oncology. This partnership is designed to streamline the process of genetic testing, ensuring that better healthcare solutions are readily available to patients and healthcare providers alike.
Introduction of MyRisk Testing into OncoEMR
At the forefront of this partnership is the integration of Myriad’s MyRisk test, which is notably the first hereditary cancer test incorporated into Flatiron’s OncoEMR platform. With this integration, healthcare providers can easily order the MyRisk test and access its results through their existing electronic medical record (EMR) system. This seamless integration marks a milestone in making important genetic information more accessible to clinicians, thus facilitating timely decision-making in patient care.
Enhancing Access to Genetic Testing
The collaboration enables a vast network of healthcare professionals—over 4,200 providers at more than 800 community-based cancer care facilities across the nation—to access MyRisk testing efficiently. Clinicians can order and receive test results within their daily workflow, which not only increases efficiency but reduces the administrative burden that often accompanies genetic testing.
Aims to Improve Patient Outcomes
The coordination between Myriad Genetics and Flatiron Health emphasizes improving patient outcomes through personalized medicine. George Daneker Jr, MD, President and Chief Clinical Officer of Oncology at Myriad Genetics, articulates the goal of enhancing the usability of germline testing integrated within the existing workflows of practitioners. This collaboration is expected to simplify the process of ordering genetic tests, thereby supporting healthcare providers in obtaining crucial health data that could significantly influence treatment decisions and ultimately enhance patient care.
Personalized Medicine: A Key Focus
Personalized medicine plays a pivotal role in modern healthcare, particularly in oncology where tailored treatment plans can make a significant difference in patient outcomes. Stephen Speicher, MD, Senior Medical Director at Flatiron Health, highlights that improving access to germline testing at the point of care is essential for refining treatment strategies. This partnership equips physicians with the necessary resources to implement precision medicine effectively, giving them more time to focus on patient interactions and enhancing the overall patient experience.
The Future of Genetic Testing in Oncology
As the integration of MyRisk testing into OncoEMR becomes available to users, there’s a broader vision for expansion. Myriad Genetics aims to incorporate other genomic testing solutions into Flatiron’s platform in the future. This expansion reflects a commitment to addressing the diverse needs of patients and healthcare providers, ensuring they have access to a range of genetic insights that can guide clinical decision-making.
About Myriad Genetics
Myriad Genetics is dedicated to advancing health and well-being through genetic testing and precision medicine. The company focuses on developing tests that assess the risk of diseases and assist in treatment decisions across various medical fields. Their innovations are aimed at improving patient care and reducing healthcare costs.
About Flatiron Health
Flatiron Health is at the forefront of using technology to enhance cancer care. Their efforts are focused on transforming data into actionable insights to improve real-life experiences for cancer patients and create a more connected healthcare ecosystem. Their use of machine learning and real-world evidence sets them apart as a leader in the healthcare technology space.
Frequently Asked Questions
1. What is the significance of the partnership between Myriad Genetics and Flatiron Health?
This partnership aims to enhance the accessibility of genetic testing, notably the MyRisk test, making it easier for healthcare providers to order and review results, which can lead to better patient outcomes.
2. How does the MyRisk test integration work?
The MyRisk test is integrated into Flatiron’s OncoEMR platform, allowing providers to order tests and access results directly within their existing workflows, promoting efficiency and ease of use.
3. Who will benefit from the integration of MyRisk testing?
Patients and healthcare providers at over 800 cancer care locations across the U.S. will benefit, as it streamlines the genetic testing process and improves patient care.
4. What are the future plans of Myriad Genetics regarding this partnership?
Myriad Genetics plans to expand their genomic testing solutions on the OncoEMR platform to further meet the needs of patients and healthcare providers.
5. Why is personalized medicine important in cancer treatment?
Personalized medicine tailors treatment to individual patient needs, which can significantly improve outcomes and ensure that patients receive the most effective therapies for their specific conditions.
